The influence of EGFR on this signature was demonstrated by its overlap with that of EGFR-transfected MCF-7 cells and the presence of known EGFR transcriptional targets, including PTGS2, the ErbB ligands EREG and AREG, and Met, a receptor tyrosine kinase that was recently reported to be activated in EGFR-mutant NSCLC cells and to promote TKI resistance in these cells [8;27–29]. Here, MET is linked to non-small cell lung carcinoma.